ABCSG 25/PANTHER Summary
Randomized phase-III-study; Comparing biweekly and tailored epirubicin and cyclophosphamide followed by biweekly tailored docetaxel (dtEC, dtT) (A-arm) vs. three weekly epirubicin and cyclophosphamide, 5-fluorouracil followed by docetaxel (FEC, T) (B-arm) in lymph node positive or high risk lymph node negative breast cancer patients – a continuation of the feasibility part of the SBG 2004-1.
|Finish:||09/2011, Follow Up ongoing|
|Coordinating investigator:||Greil, Richard; Salzburg|
|Sample size:||national 450, international 2.000|
(Click to enlarge)